Key result
Statin therapy for hyperlipidemia reduces stroke risk across summarized trials.
Why the study?
Because cardiovascular diseases and stroke are becoming the main challenge in healthcare, this study aimed to assess hyperlipidemia as a predictive risk factor for these conditions.
Answers are grounded in this paper and cite their sources.
Statin therapy should be prioritized for hyperlipidemia to lower stroke risk; confirms benefits across RCTs and bolsters guideline recommendations.
Background: Cardiovascular diseases and stroke are becoming the main challenge in the healthcare field, and this has required the study of their risk factors.Aim: The aim of this study is to assess the hyperlipidaemia as a risk factor for cardiovascular diseases and stroke.Method: Published clinical trials of hyperlipidemia studies were recognized by a search of EMBASE and MEDLINE databases with keywords hyperlipidemia, stroke or cardiovascular disease, or prospective study, and meta-analysis.Results: Cardiovascular and stroke prevention begin with recognizing their risk factors, many randomized trials of statins have revealed a decrease in the chance of cardiovascular diseases and stroke linked to the decrease in the lipid intensity.Conclusion: after the summarized of all the studies stated in this review, it can be recognized that hyperlipidemia is a significant risk factor for cardiovascular diseases and stroke and correlated in patients with atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Alloubani et al. (2017) conducted a review in Hyperlipidemia, cardiovascular disease, and stroke. Lipid-lowering therapy (statins) vs. Placebo or standard care was evaluated on Cardiovascular disease and stroke. Statin therapy to treat hyperlipidemia reduced the risk of stroke by 10% to 50% across summarized randomized clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: